Cargando…
Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia
Most patients with pancreatic adenocarcinoma (PDAC) suffer cachexia; some do not. To model heterogeneity, we used patient-derived orthotopic xenografts. These phenocopied donor weight loss. Furthermore, muscle wasting correlated with mortality and murine IL-6, and human IL-6 associated with the grea...
Autores principales: | Rupert, Joseph E., Narasimhan, Ashok, Jengelley, Daenique H.A., Jiang, Yanlin, Liu, Jianguo, Au, Ernie, Silverman, Libbie M., Sandusky, George, Bonetto, Andrea, Cao, Sha, Lu, Xiaoyu, O’Connell, Thomas M., Liu, Yunlong, Koniaris, Leonidas G., Zimmers, Teresa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185651/ https://www.ncbi.nlm.nih.gov/pubmed/33851955 http://dx.doi.org/10.1084/jem.20190450 |
Ejemplares similares
-
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin
por: Zhong, Xiaoling, et al.
Publicado: (2022) -
The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
por: Au, Ernie D., et al.
Publicado: (2017) -
In Vitro, In Vivo, and In Silico Methods for Assessment of Muscle Size and Muscle Growth Regulation
por: Rupert, Joseph E., et al.
Publicado: (2020) -
STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2011) -
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
por: Zhong, Xiaoling, et al.
Publicado: (2019)